A carregar...
Publicação
Lipid alterations in neurodegenerative diseases: from pathogenesis to potential therapies: focus on Alzheimer’s Disease
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Existe uma relação complexa entre o metabolismo lipídico e a doença de Alzheimer, uma doença neurodegenerativa e a principal causa de demência. À medida que a população mundial envelhece, a incidência da doença de Alzheimer continua a aumentar, apresentando desafios significativos aos sistemas de saúde no mundo inteiro, representando um fardo social e de saúde significativo. Este trabalho explora a patogénese da doença de Alzheimer, enfatizando fatores genéticos e ambientais, como dieta e metabolismo lipídico.
Alterações lipídicas específicas, incluindo alterações nos glicerofosfolipídios, esfingolipídios e níveis de colesterol, são consistentemente observadas em pacientes com doença de Alzheimer. Estas alterações lipídicas contribuem para a formação de placas amiloides e nós neurofibrilares, exacerbando o dano neuronal e o declínio cognitivo. Fatores genéticos, particularmente a presença do alelo ApoE4, influenciam significativamente o metabolismo lipídico e estão associados a um risco aumentado de desenvolvimento da Doença de Alzheimer. O alelo ApoE4 afeta o metabolismo dos esfingolipídios e do colesterol, levando à acumulação de lipídios no cérebro e promovendo a patogénese da doença de Alzheimer. Fatores ambientais, como a dieta, também desempenham um papel, com elevada ingestão de gordura saturada e baixo teor ácidos gordos polinsaturados (PUFAs), contribuindo para a desregulação lipídica e aumentando o risco de Alzheimer.
Apesar do potencial promissor das estratégias terapêuticas baseadas em lipídios, desafios como a complexidade das interações lipídicas no cérebro, a passagem através da barreira hematoencefálica e a variabilidade individual na resposta ao tratamento devem ser abordados. No entanto, alguns estudos pré-clínicos e clínicos a decorrer, estão a explorar novas estratégias como modificações dietéticas, melhoria do transporte lipídico e regulação do metabolismo do colesterol, usando tanto moléculas pré-existentes como moléculas recentemente desenvolvidas. Estes estudos apresentam oportunidades e desafios na passagem dos resultados das pesquisas para a aplicação clínica.
No entanto, ainda há necessidade de uma compreensão mais profunda do metabolismo lipídico na Doença de Alzheimer, uma vez que a sua prevalência mundial continua a aumentar. Um avanço continuo neste campo de pesquisa poderá oferecer novos potenciais caminhos terapêuticos, aumentando a qualidade de vida e influenciando a progressão da doença em pacientes futuros.
There is an intricate relationship between lipid metabolism and Alzheimer's disease, a prevalent neurodegenerative disorder and the leading cause of dementia. As the global population ages, the incidence of Alzheimer’s disease continues to rise, presenting significant challenges to health systems worldwide and posing a significant societal and healthcare burden. This work explores the pathogenesis of Alzheimer’s Disease, emphasizing genetic and environmental factors such as genetics, diet, and lipid metabolism. Specific lipid alterations, including changes in glycerophospholipids, sphingolipids, and cholesterol levels, are consistently observed in Alzheimer’s Disease patients. These lipid changes contribute to the formation of amyloid plaques and neurofibrillary tangles, exacerbating neuronal damage and cognitive decline. Genetic factors, particularly the presence of the ApoE4 allele, significantly influence lipid metabolism and are associated with an increased risk of developing Alzheimer’s Disease. The ApoE4 allele affects sphingolipid and cholesterol metabolism, leading to lipid accumulation in the brain and promoting Alzheimer’s Disease pathogenesis. Environmental factors such as diet also play a role, with high saturated fat intake and low omega-3 polyunsaturated fatty acids (PUFAs) contributing to lipid dysregulation and increased Alzheimer's risk. Despite the promising potential of lipid-based therapeutic strategies, challenges such as the complexity of lipid interactions in the brain, delivery across the blood-brain barrier, and individual variability in treatment response must be addressed. Nevertheless, ongoing preclinical and clinical studies are exploring novel strategies such as dietary modifications, enhancement of lipid transport, and regulation of cholesterol metabolism, using both existent and newly developed molecules. These efforts present opportunities and challenges in translating research findings into clinical applications. However, there is still a need for a deeper understanding of lipid metabolism in Alzheimer’s Disease, given its increasing global prevalence. Continuous advancements in this field of research might offer new insights into potential therapeutic avenues, ultimately improving quality of life and influence disease progression for future patients.
There is an intricate relationship between lipid metabolism and Alzheimer's disease, a prevalent neurodegenerative disorder and the leading cause of dementia. As the global population ages, the incidence of Alzheimer’s disease continues to rise, presenting significant challenges to health systems worldwide and posing a significant societal and healthcare burden. This work explores the pathogenesis of Alzheimer’s Disease, emphasizing genetic and environmental factors such as genetics, diet, and lipid metabolism. Specific lipid alterations, including changes in glycerophospholipids, sphingolipids, and cholesterol levels, are consistently observed in Alzheimer’s Disease patients. These lipid changes contribute to the formation of amyloid plaques and neurofibrillary tangles, exacerbating neuronal damage and cognitive decline. Genetic factors, particularly the presence of the ApoE4 allele, significantly influence lipid metabolism and are associated with an increased risk of developing Alzheimer’s Disease. The ApoE4 allele affects sphingolipid and cholesterol metabolism, leading to lipid accumulation in the brain and promoting Alzheimer’s Disease pathogenesis. Environmental factors such as diet also play a role, with high saturated fat intake and low omega-3 polyunsaturated fatty acids (PUFAs) contributing to lipid dysregulation and increased Alzheimer's risk. Despite the promising potential of lipid-based therapeutic strategies, challenges such as the complexity of lipid interactions in the brain, delivery across the blood-brain barrier, and individual variability in treatment response must be addressed. Nevertheless, ongoing preclinical and clinical studies are exploring novel strategies such as dietary modifications, enhancement of lipid transport, and regulation of cholesterol metabolism, using both existent and newly developed molecules. These efforts present opportunities and challenges in translating research findings into clinical applications. However, there is still a need for a deeper understanding of lipid metabolism in Alzheimer’s Disease, given its increasing global prevalence. Continuous advancements in this field of research might offer new insights into potential therapeutic avenues, ultimately improving quality of life and influence disease progression for future patients.
Descrição
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, 2024, Universidade de Lisboa, Faculdade de Farmácia.
Palavras-chave
Alzheimer’s disease Lipid metabolism ApoE4 Cholesterol Tau protein Amyloid-β Mestrado integrado - 2024